Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on February 26, 2018. The filing serves to announce company highlights and financial results for the fourth quarter and full-year ended December 31, 2017.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes
The filing does not explicitly detail material changes versus the prior comparable period within the main text. It directs readers to the attached press release for the announcement of fourth quarter and full-year results.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information disclosed under Item 2.02 and Exhibit 99.1 is being "furnished" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Consequently, this information is not incorporated by reference into other registration statements unless expressly set forth. No specific guidance, outlook, or risk factors are detailed in the provided text.
Investor Verification Checklist
- Verify the correct registrant name is Trovagene, Inc., not Cardiff Oncology, Inc.
- Review Exhibit 99.1 (Press Release dated February 26, 2018) for actual financial figures and operational highlights.
- Confirm the specific details of the fourth quarter and full-year 2017 results as they are not present in the 8-K body text.
- Note that the financial data in the press release is furnished, not filed, which may affect its legal standing in other contexts.